Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia

Journal of Clinical Lipidology

Volumn 9, Issue 3, 2015, Pages 384-389

  Lemus, Hernán N ^a   Mendivil, Carlos O ^a,b  

^a UNIVERSIDAD DE LOS ANDES   (Colombia)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

Author keywords

AMPK; ATP citrate lyase; Cholesterol; Dyslipidemia; ETC 1002; Hypercholesterolemia; LDL; Lipid metabolism; Statin intolerance

Indexed keywords

5' ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE INHIBITOR; PROTEIN KINASE; UNCLASSIFIED DRUG; 8-HYDROXY-2,2,14,14-TETRAMETHYLPENTADECANEDIOIC ACID; CHOLESTEROL; COENZYME A; DICARBOXYLIC ACID; FATTY ACID;

DRUG EFFICACY; DRUG TARGETING; DYSLIPIDEMIA; ENZYME INHIBITION; HUMAN; LIPOGENESIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DYSLIPIDEMIAS; ENZYMOLOGY; METABOLISM;

ANIMALS; ATP CITRATE (PRO-S)-LYASE; CHOLESTEROL; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; COENZYME A; DICARBOXYLIC ACIDS; DYSLIPIDEMIAS; FATTY ACIDS; HUMANS;

EID: 84931570425     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2015.01.002     Document Type: Review

References (32)

1. Cholesterol Treatment Trialists' (CTT) Collaborators B. Mihaylova, J. Emberson, and L. Blackwell The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
2. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. F. Taylor, M.D. Huffman, and A.F. Macedo Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 CD004816
4. E. Matteucci, and O. Giampietro Statin intolerance: why and what to do - with a focus on diabetic people Curr Med Chem 20 2013 1397 1408
5. L.S. Rallidis, K. Fountoulaki, and M. Anastasiou-Nana Managing the underestimated risk of statin-associated myopathy Int J Cardiol 159 2012 169 176
6. M. Alberton, P. Wu, E. Druyts, M. Briel, and E.J. Mills Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis QJM 105 2012 145 157
7. D.I. Swerdlow, D. Preiss, K.B. Kuchenbaecker DIAGRAM Consortium MAGIC Consortium InterAct Consortium HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials Lancet 2014 10.1016/S0140-6736(14)61183-1
8. S. Erqou, C.C. Lee, and A.I. Adler Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis Diabetologia 2014 10.1007/s00125-014-3374-x
9. M.P. Hermans, M. Castro Cabezas, and T. Strandberg Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries Curr Med Res Opin 26 2010 445 454
10. L.A. Leiter, P. Lundman, P.M. da Silva, H. Drexel, C. Jünger, A.K. Gitt DYSIS investigators Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study Diabet Med 28 2011 1343 1351
11. R.T. Dadu, and C.M. Ballantyne Lipid lowering with PCSK9 inhibitors Nat Rev Cardiol 11 2014 563 575
12. Q. Wang, S. Li, and L. Jiang Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice J Lipid Res 51 2010 2516 2526
13. T. Sun, K. Hayakawa, and M.E. Fraser ADP-Mg2+ bound to the ATP-grasp domain of ATP-citrate lyase Acta Crystallogr Sect F Struct Biol Cryst Commun 67 2011 1168 1172
14. T. Sun, K. Hayakawa, K.S. Bateman, and M.E. Fraser Identification of the citrate binding site of human ATP-citrate lyase using X-ray crystallography J Biol Chem 285 2010 27418 27428
15. N. Zaidi, J.V. Swinnen, and K. Smans ATP-citrate lyase: a key player in cancer metabolism Cancer Res 72 2012 3709 3714
16. Y. Wang, Y. Wang, L. Shen, Y. Pang, Z. Qiao, and P. Liu Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer Oncol Rep 27 2012 1156 1162
17. F. Ameer, L. Scandiuzzi, S. Hasnain, H. Kalbacher, and N. Zaidi De novo lipogenesis in health and disease Metabolism 63 2014 895 902
18. A. Gorin, L. Gabitova, and I. Astsaturov Regulation of cholesterol biosynthesis and cancer signaling Curr Opin Pharmacol 12 2012 710 716
19. N.B. Ruderman, D. Carling, M. Prentki, and J.M. Cacicedo AMPK, insulin resistance, and the metabolic syndrome J Clin Invest 123 2013 2764 2772
20. M. Schreurs, F. Kuipers, and F.R. van der Leij Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome Obes Rev 11 2010 380 388
21. H.M. O'Neill, G.P. Holloway, and G.R. Steinberg AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity Mol Cell Endocrinol 366 2013 135 151
22. S. Filippov, S.L. Pinkosky, and R.S. Newton LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase Curr Opin Lipidol 25 2014 309 315
23. S.L. Pinkosky, S. Filippov, and R.A. Srivastava AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism J Lipid Res 54 2013 134 151
24. L.J. Sharpe, and A.J. Brown Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) J Biol Chem 288 2013 18707 18715
25. C.M. Ballantyne, M.H. Davidson, and D.E. Macdougall Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial J Am Coll Cardiol 62 2013 1154 1162
26. S. Filippov, S.L. Pinkosky, and R.J. Lister ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK J Lipid Res 54 2013 2095 2108
27. D. MacDougall, J. Vanderlugt, and N. Rosenberg ETC-1002, a modulator of adenosine monophosphate-activated protein kinase and adenosine triphosphate-citrate lyase, was safe and reduced low-density lipoprotein-cholesterol in healthy volunteers J Am Coll Cardiol 61 Suppl 1 2013 E1463
28. H.N. Abramson The lipogenesis pathway as a cancer target J Med Chem 54 2011 5615 5638
29. G. Rose-Kahn, and J. Bar-Tana Inhibition of lipid synthesis by beta beta'-tetramethyl-substituted, C14-C22, alpha, omega-dicarboxylic acids in cultured rat hepatocytes J Biol Chem 260 1985 8411 8415
30. G. Rose-Kahn, and J. Bar-Tana Inhibition of rat liver acetyl-CoA carboxylase by beta, beta'-tetramethyl-substituted hexadecanedioic acid (MEDICA 16) Biochim Biophys Acta 1042 1990 259 264
31. M.J. Gutierrez, N.L. Rosenberg, and D.E. Macdougall Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus Arterioscler Thromb Vasc Biol 34 2014 676 683
32. Esperion Therapeutics: ETC-1002 phase 1 and phase 2 clinical trials, as of October 2014. Available at: http://www.esperion.com/therapies-progress/etc-1002/. Accessed last time on October 10, 2014.